Reply to D. Dierickx et al

Journal of Clinical Oncology

Volumn 28, Issue 21, 2010, Pages

  Evens, Andrew M ^a   Smith, Sonali M ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTINEOPLASTIC AGENT; CARMUSTINE; CYTARABINE; LACTATE DEHYDROGENASE; METHOTREXATE; RITUXIMAB;

ALBUMIN BLOOD LEVEL; BRAIN RADIATION; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RELAPSE; CANCER RISK; CLINICAL EVALUATION; DRUG MEGADOSE; HUMAN; HYPOALBUMINEMIA; IMMUNOSUPPRESSIVE TREATMENT; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LETTER; LYMPH NODE BIOPSY; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN TRANSPLANTATION; OVERALL SURVIVAL; POST TRANSPLANTATION LYMPHOPROLIFERATIVE DISEASE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; RISK FACTOR; SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA; TREATMENT RESPONSE;

EID: 77958594599     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.28.8597     Document Type: Letter

References (14)

1. Dierickx D, Delforge M, Verhoef G: Prognostic factors and scores in post-transplantation lymphoproliferative disorders after solid organ transplantation. J Clin Oncol 28:e368, 2010
2. Evens AM, David KA, Helenowski I, et al: Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: Outcomes and prognostic factors in the modern era. J Clin Oncol 28:1038-1046, 2010
3. Caillard S, Lelong C, Pessione F, et al: Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: Report of 230 cases from the French Registry. Am J Transplant 6:2735-2742, 2006 (Pubitemid 44571695)
4. Knight J, Tsodikov A, Cibrik D, et al: Lymphoma after solid organ transplantation: Risk, response to therapy, and survival at a transplantation center. J Clin Oncol 27:1-12, 2009
5. Leblond V, Dhedin N, Mamzer Bruneel MF, et al: Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol 19:772-778, 2001 (Pubitemid 32119092)
6. Buell JF, Gross TG, Hanaway MJ, et al: Posttransplant lymphoproliferative disorder: Significance of central nervous system involvement. Transplant Proc 37:954-955, 2005 (Pubitemid 40590756)
7. Maecker B, Jack T, Zimmermann M, et al: CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation. J Clin Oncol 25:4902-4908, 2007 (Pubitemid 350220420)
8. Cavaliere R, Petroni G, Lopes MB, et al: Primary central nervous system post-transplantation lymphoproliferative disorder: An International Primary Central Nervous System Lymphoma Collaborative Group report. Cancer 116:863-870
9. Gavrilovic IT, Hormigo A, Yahalom J, et al: Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 24:4570-4574, 2006 (Pubitemid 46630953)
10. Nabors LB, Palmer CA, Julian BA, et al: Isolated central nervous system posttransplant lymphoproliferative disorder treated with high-dose intravenous methotrexate. Am J Transplant 9:1243-1248, 2009
11. Taj MM, Messahel B, Mycroft J, et al: Efficacy and tolerability of high-dose methotrexate in central nervous system positive or relapsed lymphoproliferative disease following liver transplant in children. Br J Haematol 140:191-196, 2008 (Pubitemid 350265042)
12. Choquet S, Oertel S, Anagnostopoulos I, et al: Results of the largest study on post-transplant-lymphoproliferations (PTLDs) of the central nervous system (CNS) in the rituximab era: A surprising overrepresentation of kidney transplantations, key importance of methotrexate, cytarabine and radiotherapy for long term survival and low impact of rituximab. Blood 112, 2008 (abstr 3614)
13. Moise L, Matta C, Pilorge S, et al: High-dose methotrexate and cytarabine chemotherapy may be effective and safe in solid organ transplant recipients with primary CNS lymphomas (PCNSL). Blood 112, 2008 (abstr 3611)
14. Kordelas L, Trenschel R, Koldehoff M, et al: Successful treatment of EBV PTLD with CNS lymphomas with the monoclonal anti-CD20 antibody rituximab. Onkologie 31:691-693, 2008